ViiV gets CRL from FDA for rilpivirine and cabotegravir to treat HIV
Category: #health  By Mateen Dalal  Date: 2019-12-23
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

ViiV gets CRL from FDA for rilpivirine and cabotegravir to treat HIV

HIV AIDS cases have been prevailing and increasingly growing across the world. Currently, about 37.9 million people are suffering from HIV globally. Several global pharmaceutical firms are increasingly working and investing heavily in R&D to find new therapies to treat people suffering from HIV. Additionally, several companies are also actively spreading awareness about this disease.    

ViiV Healthcare, a renowned pharmaceutical company working towards finding new treatments for HIV, reportedly announced that it received a CRL (complete response letter) from the US FDA (Food and Drug Administration). The company received CLR for its application for rilpivirine and cabotegravir long-acting regimen. These regimens developed by the company would be used to treat HIV-1 infection for virologically suppressed adults.  

The factors mentioned in the CRL correlate to CMC (Chemistry Manufacturing and Controls). No safety issues have been reported related to CMC. Additionally, no change is seen in the safety profile of the products that are utilized in clinical studies to date. ViiV Healthcare would closely work alongside the FDA to understand the next steps that are suitable for the New Drug Application. 

Cabotegravir is an integrase strand transfer inhibitor created by ViiV Healthcare while rilpivirine, created by Janssen Sciences Ireland UC, is a non-nucleoside reverse transcriptase inhibitor. The rilpivirine and cabotegravir long-acting regimen is still an investigational product. In fact, it has not been approved anywhere in the world.

The company submitted the application for rilpivirine and cabotegravir for testing to FDA back in April. Recently, the company also marked the submission of DTG (dolutegravir), which If approved by FDA and EMA, would become the first-ever dispersible formulation therapy made for children suffering from HIV.  

About ViiV:

ViiV Healthcare is a popular biopharmaceutical company established in November 2009 by Pfizer and GlaxoSmithKline. The company is an HIV specialist and is dedicated to providing advances in therapy and care for the people suffering from HIV. The company also works for people who are at risk of being infected from HIV. Shionogi linked with the company in October of 2012.

The primary aim of the company is to take a deeper interest in HIV/AIDS and its treatment, more than any other company and further gain a new insights that help find treatment for HIV. The company also aims to help communities affected with the disease.

 

Source credit: https://viivhealthcare.com/en-gb/media/press-releases/2019/december/complete-response-letter-from-us-fda/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...